> ## Content Index
> Fetch the complete content index at: https://www.biostockinfo.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BIOTECH CATALYST AI SCANNER — September WK4
- URL: https://www.biostockinfo.com/biotech-catalyst-ai-scanner-september-wk4/
- Published: 2026-09-19T14:29:43.000Z
- Updated: 2026-09-19T14:33:17.000Z
- Author: Alex
- Tags: AI, Biotech Catalysts, Biotech Investing, Catalyst Calendar, Catalyst Scanner, Catalyst, Machine Learning

| BIOSTOCKINFO / CATALYST SCANNERScan date 2026-09-19 · 10 featured · 10 watchlistThe tapeXBI closed September 18 at 156.72: +0.3% over one week, -7.6% over one month, +11.4% over three months, +29.0% year to date, and -7.6% from its 52-week high of 169.55\. In contrast, the S&P 500 (SPY) closed at 761.69: -0.3% over one week, -1.0% over one month, +2.0% over three months, +11.5% year to date, and -2.1% from its 52-week high of 777.88\. The modest weekly divergence reflects sector-specific resilience rather than broad market momentum.Breadth remains compressed, with 30% of the 5,915 tracked US small and mid caps closing above their 20-day average on September 18\. This narrow foundation suggests that clinical catalysts must deliver clean, unambiguous efficacy to overcome defensive positioning across developmental biotech.The US 10-year Treasury yield stood at 5.00% on September 18: +2 bp over one week, +55 bp over three months, near its 52-week high of 5.01% against a low of 3.95%.This week at a glanceTICKERCATALYSTDATERANK**FTH**Topline Data, PIKTORyear-end 202684**IONS**PDUFA, bepirovirsenOct 26, 202683**FBIO**Topline Data, Triplexlate 202682**AGIO**PDUFA, PYRUKYND (mitapivat)Nov 1, 202682**AKBA**Topline Data, Vafseo (vadadustat)in Q4 202680**RAPP**Topline Data, RAP-219October 202680**EIKN**Conference Presentation, EIK1003Oct 23, 202680**PALI**Conference Presentation, PALI-2108Oct 9–Oct 14, 202680**IMCR**Topline Data, KIMMTRAK (tebentafusp)as early as the end of 202680**NAMS**Topline Data, obicetrapibby year end 202680Top 10 names by scanner score, highest first. Rank is the scanner’s score out of 100.FeaturedFTH — Faeth TherapeuticsCATALYST**year-end 2026**Data readoutRANK**84**PRICE**$34.50**+7% 20dCAP**$892M**(26M sh)CASH**$179M**\~63 mo**Faeth Therapeutics expects topline data from its Phase 2 Study FTH-PIK-201 evaluating PIKTOR in second-line advanced endometrial cancer by year-end 2026 (company's words; quarter-level precision).** The readout determines whether simultaneous multi-node inhibition delivers sufficient single-agent activity in advanced gynecologic tumors.**Company.** Faeth Therapeutics is a clinical-stage oncology company developing all-oral multi-node inhibitors of the PI3K/AKT/mTOR pathway. Following its combination with Sensei Biotherapeutics, it has no commercial revenue, with an additional Phase 1b/2 breast cancer trial reading out in 2027.**Science & competition.** PIKTOR simultaneously blocks PI3K, AKT, and mTOR signaling nodes to prevent cancer cells from activating bypass resistance pathways. Rivals include Pembrolizumab (Merck, FDA-approved) and Lenvatinib (Eisai, FDA-approved). Frontline treatment is carboplatin plus paclitaxel with an anti–PD-1 inhibitor, followed by maintenance immunotherapy.Sources: [moffitt.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGBXg8jn2zJJ0xlNMCrfnpfUFody-aGYu6aeL861BrWsHMudaiYOfEgMif24LrB7CxTO8rbVwY%5FFu3bPtUCxHJSla7wTkshWx4IlL5pMTi2r4HMOJpr6AlzcMk2fr1kvUex3DZBwFT9pDRlwkFl8tsF9HJjhLUDMMp3TKfWZAix1I1wdDkCpevewqAfQq4UVMO5Xhv2K8SHqPVd5u8s%5F-A2nUopbtzW1PCpN1eG4qTgPgtEpklLtbOXUzzu4wN0e0Tclt7M3spMvTzaMdY89VsVrV69t2XH84GPUy7dAAP-I3yBigelQNPFGaE=?ref=biostockinfo.com) · [fda.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGXQhTDJywhJO9UIEvLQg7wDHrTVrrWvwaieY3q8ek-27MVStf3eWWvWxprgRNaMILI7MamMsr3YtrEyV%5FSg7Oo2TBE91thDzI-4YtcamqKdZIhV8TQGMvdD8uuUxSbWG9eAWsoY90jYEFRIKzZ4nAWhQ3KTHSX9F-fSUkc9P57y7wV520bWxsiPuNlXTBnk5fkDq4NenWyj31xHYx8hiHuKUNkZ8OLj38IR7FR8Zkxbi3CRSkH44soxQlU-3EfSS7ljg==?ref=biostockinfo.com) · [fda.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFT-O5nwmkFmrU7H5YdcMwDCEIlzOEBLE0xdGiRypTKvjlml43-AFLsFYxraZCSzlRcDBbfORfwVY5tmNOJEXtfyp4ntO3Pel-ZYHhk3NNX2FHuiHFzTPTixXgKm04GQeYyvBbPchdHP0UqOhEdL1neRXjMINPn%5FF10fnJiR0GaLOIoYul-tfs-TEvDxMjkfwF4qsPik8tc28RnSuSay0jerOh40414-NQOm9PeOOA06ZxdMCDwi5tG09AiIg3QTENT2uUAwnw9bW3uUh43BJZm7uIDVzuC?ref=biostockinfo.com) · [clinicaltrials.eu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2wAkD-rRmr5HMAaGMuGu4rcgsISvtsFWDT83TPpWG7UcGUEyRglMP7eGjjUU1kzZa-4ojGf5c47haxwFoLeeGHXRT2eIRtGM95X7787SrjW7%5FEbrlDrJzBzMDFx4mYgBX3vDp-1aYtxbfNwsAXZ9%5FhL2XDXlCF0mEX4uA7yde1hcbuTBVore42TztzRDxv6JHExmWNwUjCBini5CH%5F2OdameaM9X7yZr0?ref=biostockinfo.com) · [fda.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFrrVnv0CgWlQUXzkKqFJMxolg58NR7E0Hb-8J3GKvMOOEKEHSRbSylVsP9GJks21h4EJh2-F6LJryqoQnKT0zTzecnC-pajWsjRPASwEIL9IzD3YjxTL-lRVs6IxYO44ZogafW0Ya8W7ckUiHnm%5F-3WN8EVS3tDnlMx1J79XDEp3aCz7pNCLhJ%5FRLs34tAqDa86EqXDU3sA7kYEjz9dgMlfUmkshz9eq31axdaY5riQwrVtt0rBIJBgHf2SmXz6eWV632SH16ox0owA7c3ksp1tusaYlggjA==?ref=biostockinfo.com) · [daiichisankyo.us](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQVURAxLPhUZbpjgCzWDgVDMs1z1h8EOxVvFg%5F2DQtavcawtl5RwTA-GnUyzMwEnLagBN%5FGjR7AoHYEK9E7An6AMhq5JfS-af8D8ACOy5%5F%5FEvtxkJPSHVtQOO2n6JpdrrgMk5akaFmFy0NDGhO7ObU8bC%5FisjmmRqY8e4JsgqMS79-%5Fsu5hIfEIiRTvMPNAkjtQ08cfaOSVXUsOI3E1ksTHxU6tHJlnhxJ-ndV77DnJgmedKWZAxNJhviMHN7Rhz2I08gBXuyF9xDqZ4ja5UpWJhrDj6%5FaBSqnobWBQ5zAf%5FjUv0g9WS9wrCqQIlVa?ref=biostockinfo.com) · [daiichisankyo.us](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEHV8aDhZZduF1HkQiHK8zoW2McU%5FEXp3Z74w2eu90uJbiv1p0F9SFXI8TjoJJc0RvGOdnocIpO9rZRIx-sV0KgfHzD29U6CDVq9khw3c0N96TEyy%5FHeKKYx8WX1ps8hOalW3REIA72sYBPIWfinfNFHA0gJfHNmV9DqDzfRC8giabXTYrMN2xQ4grq8WEvV3hY7JkSDRSpc4qg-Ns6gHTttEzN299eq22MRC3C370v29TMl3R1ORsmyv1FySwgrhPDowPBtxpljn69iDJ7K5dHnLND7lIujLbcqFzmuzj42WgX6sIZSSG13z8D8esjmkZhxUXklWFECGkjKgVlaJwFM6wbe1QkwlproE4Hsgs=?ref=biostockinfo.com) · [healthtree.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF%5F4Crh-3bRsFgS5w6MpO4dfmYCyhgVO24yiiiUHgD66TKGEZQZMueRdiuinYjkWDz2hF22QbSxlUon9Rz2Mvp-xjjIkL9CpMOQuiiWnoc73G1iCO83Cp1z0o9wdhjAk28aywnIc-Wee3dJi%5Fs2pD47DfBmU1QwMbk9V%5FbA-O7OMUDuT0G-lA==?ref=biostockinfo.com)**Why it could work.** Simultaneous pathway blockade conceptually overcomes rapid bypass resistance, backed by a prior Phase 2 trial meeting its primary endpoint in platinum-resistant ovarian cancer.**Why it could fail.** Broad pathway inhibition risks severe class toxicities like hyperglycemia and rash, while historical endometrial efficacy rested on only six evaluable patients.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=FTH&ref=biostockinfo.com)IONS — Ionis PharmaceuticalsCATALYST**Oct 26, 2026**RegulatoryRANK**83**PRICE**$44.44**\-24% 20dCAP**$7.4B**(166M sh)CASH**$2.0B**\~48 moBTDFTDPriority Review**The FDA has granted Priority Review for bepirovirsen in chronic hepatitis B with a PDUFA action date of Oct 26, 2026.** BTD, FTD, Priority Review\*\*\*\* The agency's decision decides whether Ionis and partner GSK establish the first finite-duration functional cure therapy in chronic hepatitis B.**Company.** Ionis Pharmaceuticals commercializes and develops RNA-targeted antisense medicines for neurological and cardiometabolic indications. Commercial revenue includes independent launch ZANVASTRO alongside royalties from partners Novartis, AstraZeneca, GSK, Roche, and Biogen, while targeting cash-flow breakeven in 2028.**Science & competition.** Bepirovirsen is an antisense oligonucleotide designed to bind hepatitis B viral RNA, halting replication and reducing surface antigen to restore immune function. Rivals include AHB-137 (AusperBio, Phase 3 (China) / Phase 2 (Global)) and GST-HG141 (Fujian Akeylink / Cosunter, Phase 3). The standard of care is long-term oral nucleos(t)ide analogues or finite 48-week pegylated interferon alfa-2a.Sources: [umn.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHGiIPpSDw65k%5FHemRstCuQ8PzTk1kGYJtmtWt67vCLFlnorULS1N2ImALoxgR9hXMrjivs9xWYIkZNve1aALmOQrYdYu3aOl5mRAKy7QSmDMYJQLDTix8KxrqsP9dHONJ9jpS5rqNWEcMXcdsk7SJcTximWXn8t7IYy-I72naPj%5FeHMTySTlprMjozcQr3GCiithgNQYSslmioHKg-HcWqPAKnu9pp3tKpft2laG0=?ref=biostockinfo.com) · [biochempeg.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHA9b%5F6pEWUSmJkyfCMR0EBvCx6a4mRZ6d2GjbrcWslw7%5FB9KNvok6Vcl6gDznrb25hgKr-KQNUxBmIbD3lJi3f6CjEkh3pOEaDL57AObq2phOsWx2F8v6FWHZ6vCj1f-oOeZSqBWtf?ref=biostockinfo.com) · [touchinfectiousdiseases.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE6ywRQ4GY9G6t92YS1ONLv9F0qeL6tsJ%5Fg8fCkwPsmUmEjAiNBfNuZLHFOR5yTxUSuZ6n0bVXSf-XuPevOr2rWJ4RzqupEvBWiAyqf-pffpGKT3RFtVr2IKqMCrY1mTukmRKTa9mCXZHcate0VNRECyX7JZ4T1uvdeJgDVF893iKNZF37tIyd4n3Jtpe4N2b6VYO8Z2AjXUgEff11mYxLYVt4C2PA=?ref=biostockinfo.com) · [ionis.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFoxWi5dY-MF95HSG8HBzDgqaJvDELW2maWtXZhsFuC-hjjl-uFqu%5FHdvO-e2QtDoAw4310ePMaD8nUXCH9qv9YNdrlXtf-SdAOivzoF%5FkBm5cGUSr8tn3yPRiF3fOhs0RHybHovyU4DCZPDLlw0mr-PfA5i8z4f07O8K4agVb9%5FLGaG1LM41vf3NgTFjp9ZYC6Vpm8FBgFj5at2P5wI7sHJb8QU78E-XXrTKBqDQ==?ref=biostockinfo.com) · [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFk8YSHFTADktoko4l48K2iN2nD5r1VpOBl5hB7IMIZWyvY8X-o3n3KLE6HuVXG3Uqj56pWI8MpJm64D4vTM-Ir-Hm8G39wctIWYSDBxJj28y4DmtYvFYAPZ7jo1bCboMuBnYWIN5pd?ref=biostockinfo.com) · [oligotherapeutics.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHGxYgtI%5FrnUjziXDgeZurWqP0zLP2wv1VF1hsZYxx88iFTMEKU68Ywvb1hxXWjnKVJdzag1Vvm6y4Y7yrRb2EUzxFbvPVt2BbEshBTIrXIfDELW3rWhV8Qar5CxJDAZtQfniYMpuInGQga5OMQAwWqw4gu7sczTVVqeCdZBwNkpXv3u8AG%5FKtX6sU3xLlkX-2r8yZmQcuvCrSgDcjLTGNr9vE7RUPhafA6QnYHaMNw1poytTiAoIzApg==?ref=biostockinfo.com) · [emjreviews.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHmYFP6KNvnLhAKibV%5Fjn-Fi8Zg5vpxp6nSKQwGBYWMGxkVTkBymrqF2jddQsmewlsHDOjKshRV0m361dU8xjy-Op0VvPxZFDMWP%5FsIMi8VfshbCyTlDak6NDBZlqtOPUYPQ97rI2Vb07FhgdYkqyZqB5zzMY7%5F3pn1g4tW8x%5F8nUkeZ72wn9upKAhJ5H7i72ehUC3yLgP2fACW0VNAmpZIbC1y08lQtFcD7Ltnbtnn54ApEz3nVCPsrmWRjZA=?ref=biostockinfo.com)**Why it could work.** Phase 2b data demonstrated unprecedented durable clearance of viral surface antigen in 9% to 10% of patients receiving stable antiviral therapy.**Why it could fail.** Modest absolute cure rates and potential immune-mediated liver enzyme flares could limit labeling, leaving physicians on cheap generic antivirals.**Recent development.** On August 24, 2026, Japan's Ministry of Health, Labour and Welfare approved Hibsago (bepirovirsen) as a functional cure for chronic hepatitis B in adult patients ([ionis.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGmOnIMubKYzsNjBIy1hNyQcSDbkRgzzCY0VoC-mJlMKxx2nd1U5xjHCpqVrtJudHOKGB7jyAquXpgNq2ep3tIWyZEWU4fBkzCAdDzdAS%5Fe1yrjJuaTO1e0RfOJt3M1a1g91NykFns3Ph-gzUSHZ15k3L8JhIn7uj5qHUgTaz9KjXw=?ref=biostockinfo.com)).[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=IONS&ref=biostockinfo.com)FBIO — Fortress BiotechCATALYST**late 2026**Data readoutRANK**82**PRICE**$2.51**\-9% 20dCAP**$84M**(33M sh)CASH**$197M**no net burn**Fortress Biotech expects topline data from its fully enrolled Phase 2 trial of Triplex for the prevention and control of CMV in adults co-infected with HIV and CMV in late 2026 (company's words; quarter-level precision).** The readout determines whether a therapeutic vaccine can suppress cytomegalovirus reactivation without continuous antiviral toxicity.**Company.** Fortress Biotech acquires and develops clinical-stage assets, generating product revenue alongside equity holdings and royalty streams. Key programs include Triplex and dotinurad, alongside advancing subsidiary programs such as MB-109 in recurrent glioblastoma.**Science & competition.** Triplex uses an engineered viral vector to stimulate specialized T-cell immune responses against cytomegalovirus, preventing reactivation in immunocompromised individuals. Rivals include Valganciclovir (Valcyte) (Roche / Genentech, FDA-approved (2001) for induction and maintenance of CMV retinitis in AIDS) and Ganciclovir (Cytovene) (Roche / Genentech, FDA-approved (1989 \[IV\]) for treatment and maintenance of CMV retinitis in immunocompromised patients, including individ). The standard of care is prompt antiretroviral therapy combined with oral valganciclovir if acute treatment is required.Sources: [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFXwQLWVdP0L2tBQpxTXy1CBfNHHmoRkG34Xz-66wo4Bjy-WgejGc96iSs061NbPcW2WmGT3etkJ2d7IwvhFUAJN2x-oOoeXiMDs-vmbiP9ZS9UCM9yT-6e3Gugx6nM0cnkTUuNCbZyVr9srCI=?ref=biostockinfo.com) · [i-base.info](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE%5FugIk%5Ft%5FRfutEaP69O9VbpR-OFgFvPLmN9%5FtoBrdX9XgBlsWDXG64QxPraB7weoJ8q9UkFG6ogmJtwJN2TcAbDv00N1iD5hfQ1%5F5wzUjMvXGf7PMEkkM=?ref=biostockinfo.com) · [hopkinsguides.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQjU48X74ty1qQY4XLoB2SAOFQy%5FfvjDw6gCFGNyFPQI2XO0lBU9h3Bkclo-N6gygH6fM4Z6mlWKfmMuwEuzPH3BZfi%5FZyDCoVx10u3aIgdtogB7xT1zVTv3-VVIVtiXNjYy673tqDAFBd5OYS2Zzd9oONBerWJkJrItlJGxquPcj--WjfQJuM8IoMa-J5arhQ1VNP620=?ref=biostockinfo.com) · [gilead.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFpK69whc9ZvlxoVffDCqgjNDob--9Kx60D4yUp06nsZGuqJ2L1W2N4ASuuXr4AGQ2dUBaPHrz-OmjFcl-frZqESjtdBXfTAlmgVq5GI355xmXDnp%5FKkTq51wwZfoSdBkOiqTEdXuwijGhVdoevUU47H3SWXnr7Mo0YZjRsaDcciwFjyXjvBpom1hECSGmrCwSE8sLS9QSLaTjwvM7BgL0HFpqqYANf-JTKqoG2wrori8rGx3sAytUdo7awDTx8UdGZ8NqxvUgfD-j%5FI7HAfW11DO-oMw==?ref=biostockinfo.com) · [hiv.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFnedFErPoV%5FEDPF1D3a5yHvCt%5FaoNEWL5yp37MRg3aaOhOj8MbUgwVRkk2SMmgG-B89hiRAs4ZIMXuTki55A-nb7q1E2hcKJ81lKZKWObdEpE8ss%5FQQrAXnVYqIuveQYQ0XQH%5F3jxBPbW2cEJdDwrbU2rPAXfkIhkIk1m?ref=biostockinfo.com) · [clinicaltrialsarena.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFCgFF2zon4n4NbV48eqra9x0hpmIRSZNVQc0GVN6ISufEemjpFwNpjeiLWn7%5F4WodjqRzpbg6sO3sdUIKjzlwHUVK2R5BsoYby5pButOqnnkeOGlZ6MqciP0wWyaBRIwBcfn%5FMzLT7h50Di5JCxqPg8CmgfZDrhm0PaF831Hnnwgm%5FSOH89cMEgfDvd4MBQmJG%5FOKO7o95Rs%5FrjL5tiHpIWvDUjWVb?ref=biostockinfo.com) · [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE8q9z3gYa912pnE7No3FWUGyYPElVD%5FIub4P%5F%5FhIv235b%5F4xV3-6fYeo3NUxcd0P%5FOme5cXCRMHjPvGhA4aqnj%5F3ZDEx5%5F1KI2rA7qPL-GVnABuAnd0KqsTi49FqDEVgj-ckLy0GEbvOl%5FGPp7d6c=?ref=biostockinfo.com) · [hiv.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE8ln4ceA0o12EGXOAaT20TOj1akbhxAVNEQRu7G%5F71s0LkgMCIvCqp7WwNbI9D4CgAJkzlwkQPqLbGcSFBEVz9idXhLjDpSgJzhp%5Fl76undestdNoyOce5vGJATRX9SiKwQLd%5FKXbs4Qk49RB%5FII9fUWN7URbEZAp94Z5%5FLsp7ZV%5FKVSvN%5FgAprVVVtzLV-1EOl2XTLHkY6ymShnFWnBr0xc40Lx-dVL0hU84VRa82?ref=biostockinfo.com)**Why it could work.** Targeted T-cell activation aims to restore natural host immune control, potentially reducing viral shedding and systemic inflammation without daily small-molecule toxicities.**Why it could fail.** SEC filings omit sample size and placebo details, and anti-vector antibodies could undermine durability or yield inconclusive viral load suppression.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=FBIO&ref=biostockinfo.com)AGIO — Agios PharmaceuticalsCATALYST**Nov 1, 2026**RegulatoryRANK**82**PRICE**$33.07**\-2% 20dCAP**$2.0B**(60M sh)CASH**$920M**\~31 moFiling warning**The FDA has set a PDUFA goal date of Nov 1, 2026, for the supplemental New Drug Application of mitapivat in sickle cell disease under accelerated review.** The decision decides whether Agios expands its oral pyruvate kinase activator into non-malignant hematology following the market exit of competing therapies.**Company.** Agios Pharmaceuticals commercializes therapies for rare hematologic conditions, marketing AQVESME in thalassemia. It generates product revenue while advancing a clinical pipeline that includes mitapivat in sickle cell disease, AG-181 in PKU, and AG-236 in polycythemia vera.**Science & competition.** Mitapivat is an oral small-molecule pyruvate kinase activator that boosts red blood cell adenosine triphosphate and decreases 2,3-DPG to inhibit sickling. Rivals include Hydroxyurea (Bristol Myers Squibb / Addmedica, FDA-approved (1998 for adults; 2017 for pediatrics)) and Etavopivat (Novo Nordisk, Phase 3 completed). The standard of care is oral hydroxyurea supported by hydration, pain management, and red blood cell transfusions.Sources: [vcuhealth.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHP8mYkoxzwGhBqI62MjydyN1AgASJol6-sz8vp4kF9vUwGzWKylhwHBWGYYCuPerD30NQXfARf1Dk%5FAGlAEY33aLWcgfXv9VRzU8O9222g4JLYT0q1XWiZSHjTeoMG6mTQuFlqQnX5ti0oSLOMEsfA7bIQ9--8aU4Jnklzp05NNw96LnvAJQjapDuHdl%5F5wXLAuSXqTZQY1JbQ9PbIraUxSxMiuzNNxSVeJ6FChQ==?ref=biostockinfo.com) · [fiercebiotech.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFH6tUHgqMSto%5FKV5AXVtqGSm-j6%5FohjshIvd-kXIEd7MG9jAm7MIOzs6a1avaCd9acqzvBN01Qk8lnYTfnnv-bbwmgP%5Fc9LLjpallW-t7MREY6us4eZEBe-ClHR2V0cRO9D6P-%5FAjxX57DzozDjKHQeO5WhlO8ILedDP8UrCVe2YNnDM3yYhiqcXVijKe6KdvmPieG-O18ExQuadhaPeCYtQE4BQ==?ref=biostockinfo.com) · [medcentral.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGfZay6ZPIGdNbuf-NbrkJL1-Y9t86C8-aqEwwzLqYXv6IUQGu9IXGq7SPAlbx6rouMuUiMyX5-iAHjoLKeIfABg0O2Og4Gx8l8N368vImCEKqaNNqpIm2iNnBTSFgh9ihhy142PUkQIOJngaeHzNXfk6bRhTXtGfreT0pTYphAR-oRbo1INOtoErn9-gxhB%5Fxfo-fk9HbgYi%5FMV-VyJaTcaFM-noaPypXOHA==?ref=biostockinfo.com) · [yalemedicine.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG21IO2rTdCPlqAA5Zh2NNq0F3%5F7yjoCJmH-pnxKpheuvD6rSZim2QsSbd2Lddl1YloW7aXkfbr%5FMawL4rPmJoi8wpZBay4utt82m5Kb2KwcxhYR67vNF0Mind0TRz5YE6zX9C6ccqXPSser2acFSWFh8Czw-LVPz-G9RmSoqU8?ref=biostockinfo.com) · [clinicaltrialsarena.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFPD9dNSSHrRxgMuIZ3eiiGYbugSTcHHbbteSftdn5b-zuCOtQjRo7Oq%5FFkCkMUVKAP66305yt%5FkDpyAeRdUeJJ5UKd8e7tsW2KN0geNrrpqWoEihw9cU0uBL3YU5291aRUZe9JSpJdwq8E%5FC1AUhtrkrOOqB1y1WaJXlZg%5FUFQcMiNFae-todmHzWFsQUibgop7Kc4B1Yx-ZGjXtQibjp-u6lt%5FrylnvmmURxRlpBGK%5FP7Mw==?ref=biostockinfo.com) · [delveinsight.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG%5FM1F3zdckt0WemMQbZKZKYvseGgYwiJ8PhP5ZyoqsppCrUGBbUSsbg4b%5FpS%5FYdbq7rArA%5FwOYxBVaBY98W5-h6yT6Z0DCEK1avOxJuyN53FcOzI6ex3AQoNf8I1ACfft25StQvaOfuHuYIbVqN2fHwkgwSpR0sm1bR4-pfAJ-U0-eRkZzEIYePA==?ref=biostockinfo.com) · [openpr.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGvcy4cV1YgcyxINiJVKUyaIoCowi4JX7C%5FWVbIHZ0wdD0AjP5HtvbrU6%5FR9y1QyPgrAOoeAY2CxhqPtLhmsc8U18%5FeAKCnbbkemZipY7UU3mVVLgVNpl2kAp8ABNNEHNS9Y6E9B5NxucqdkGlnGiqkrV2UsM4YmEp64IL0KaS6S8NBFkm6oc0mr43M0J%5FZndw=?ref=biostockinfo.com) · [hcplive.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH%5FVIX1kHRD83PDPc2Lr4vaAx4XfQcnhiWhL5iAPLG-XPZhvXYhsmceb0whryHqsvfkDns8t1PGK5NLeXlDMwy5VKYKUqkQOVDlZsEufq913S7-m%5F9hGE0CR8vkN1-rgC4yaLpl7aRXoZ5YxZBZ8hCBqzAyooxEISLmbBrn9eJ%5Fs%5FkCDXLMJ3imHYWhc%5F37kA0nxeDKR1JFFntyaxQBRR40fKA=?ref=biostockinfo.com)**Why it could work.** In the Phase 3 RISE UP trial, mitapivat significantly increased hemoglobin response and reduced annualized vaso-occlusive crises in sickle cell patients.**Why it could fail.** Regulators may demand hard clinical outcomes over surrogate hemoglobin increases or impose restrictive safety monitoring on accelerated labeling.**Filing flag.** Agios announced it will not advance tebapivat in lower-risk myelodysplastic syndromes or sickle cell disease following Phase 2b and Phase 2 results.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=AGIO&ref=biostockinfo.com)AKBA — Akebia TherapeuticsCATALYST**in Q4 2026**Data readoutRANK**80**PRICE**$0.92**\-0% 20dCAP**$254M**(277M sh)CASH**$156M**no net burn**Akebia expects topline data from the Phase 3b VOCAL trial evaluating three-times-weekly dosing of Vafseo (vadadustat) in anemia due to CKD in dialysis in Q4 2026 (company's words; quarter-level precision).** The trial decides whether intermittent clinic-aligned administration can match approved once-daily dosing regimens.**Company.** Akebia Therapeutics is a commercial biopharmaceutical company marketing Vafseo for dialysis-related chronic kidney disease anemia. Commercial product revenue funds operations alongside mid-stage pipeline assets ebribafusp for glomerular kidney diseases and praliciguat.**Science & competition.** Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that mimics the physiological response to hypoxia to stimulate endogenous erythropoietin production. Rivals include Jesduvroq (daprodustat) (GSK, FDA-approved (February 2023)) and Aranesp (darbepoetin alfa) (Amgen, FDA-approved (2001)). The standard of care is injectable erythropoiesis-stimulating agents administered alongside intravenous iron supplementation.Sources: [haaselab.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEzm195OrtUifGKYc8C3wHsbAJJMInOuz6rh9C3gDzYDnfbU4C%5FN3l3ISMYsg4tgScSGKb69eI8Pq7lCIYcJJv1OiaggoEvqeDG2PeM2jjHQICTB0R3k6ZVjp1fXxyX4iYRWSI0mtFx8B6wELiFHV7dPhMaMPu2d9I5vYf5IfvD04FJG83FjdqFSkRfVEzAC44HBVRyD02IiNoW?ref=biostockinfo.com) · [ashpublications.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH6TccDktFgNQunEOUxWfKhCfe9Ji93WE6RqfqXmdqjBsCUcZzV--nJizIIS9e26BOJuh35TgOeASCF1nYEGFlBQ3I2YLu8dQuWJlCyspt6Nrj4j-1JELFLh7QzrH86-5S32PMAnGqKsx4fg-XEeU2evVTtNUkktWlPFYhYE04q%5FQTVJlmSHNtoWUcZ0sXq0AOOU4GKN0sS-p0qVSjhRvHm8E-Lo5XA1E90ePc3tw==?ref=biostockinfo.com) · [spherixglobalinsights.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEbjFnDkNLwB9Cg3mzmbu%5F5PC7f4OkJgGPZh8ZUERNaW9l84k78eOIS4PnKCnfV1zLhohqObtOFZtSd2kZwCZ4MboMqG2PTDFllE7Iihkcrhj4lCS5zWM%5FOiazhLtmHxNnHWWzxxJsZ44fGhMr1m6ucVKWJHOx2bI6C01cc02-WannBWHml76HPy%5F9dy6AGdA-%5F5S81tZTXU2vpdChIjwVdBeDQ3CU3-hM%5FdFS1ixzGtP4bhMK5%5F2h915Cs6Cl2CIQXuw==?ref=biostockinfo.com) · [fiercepharma.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHpA7TkM0MiBuQf3j-oy4xY4tP6oZj2f8vffpI0131DWmlzK09MPbsa9c02fQ94kPSLlJONQQrkh9JpIMzr0OiE7dP49-HNJJw36hkFSIT37FViMYwIB04AcQUS2UW0l2ZvFXt5MxdHRNCXzJPh696SXl-dIU5ayson%5FbN4w7mWnzRK%5FUX9%5Frd43cUVr8FSfCYz18-kpciLqkzqYIkb727pyIPHK7l-PsTbRXtJSn4SS%5FaEaXmZ9a%5FqUncaiw==?ref=biostockinfo.com) · [fda.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQER1Q38JL9UTCpqEBKuX2IL0dpgAczeCuF3DxO9rqEw25d4BzPGwmVUWZaLJy7vW0BdB9pbeFc1RBJy6w6AQ3HnnBfcrcmr5MVtdl4Z-LhOw72dRLyVElbfGf6xcSyoeY7DHx3wzCOFIoedHytYjChGRd9buQ4NsopULsgzvOPaX-Iw-Mfz2y0l7ZXthA==?ref=biostockinfo.com) · [kidneynews.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFl14%5FBu%5FVrIEiyRiKRr6r6wjK17N3Icq2durEkA6uEmrtywGz4lBH1QfDxVNfgF2Zy5G0Yd0tJkE-gMUZQS8ZFWIkDxNMuaFsTYPPK%5FzXVyySy1zRjYZM-6PNCHfQZVduawdXq3tyk1yLUD94oxVfKBUxVPBKQMwyZpwuVa8QgW3APz%5FA22Q==?ref=biostockinfo.com) · [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEskPUXGn0oIsDxpNOFfi0rgCInh2V3W46xhMGVQI8D6P5fvxDjvF1FlIT0gl8VHi14tmpeM1Al6CiGry4CBOOtkC0YZm4QO4yzmb78Pu9rMEt%5FwFoZ9RZmX1b13uZmza0iGiG7VQuG?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHxpQrpmfES6vjyMDTUR9fLm0Tkc6RuscjcnvkalaNx1PvBDElXLVIEnuQLsUB9NDZGVmjb3bP1J5Q05oRBpAUFHn96nTx6%5FuV4JaldnKnZ4mMhybHjKs98A215xxsk1vYvlbERoBLPwy2%5FUX9I?ref=biostockinfo.com)**Why it could work.** Synchronizing dosing with routine thrice-weekly dialysis clinic schedules eliminates patient home compliance hurdles, building on positive interim safety outcomes in the 2,116-patient VOICE trial.**Why it could fail.** Intermittent dosing requires higher single doses, risking peak-concentration blood pressure spikes, thrombosis, or inadequate hemoglobin maintenance.**Recent development.** On September 14, 2026, Akebia announced the first patient dosed in its Phase 2 open-label basket trial of ebribafusp in rare complement-mediated kidney diseases ([akebia.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfBFdwrkWf6bgkd7e1ZVXTtup%5Fl7g0eSm%5F%5F8pfO4TMcIUFhe7EpTFfwdenXbfc0SSxcCxgwTfmy7gvAxsicGklnortuVrbaImfxapk0oXrFCg=?ref=biostockinfo.com)).[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=AKBA&ref=biostockinfo.com)RAPP — Rapport TherapeuticsCATALYST**October 2026**Data readoutRANK**80**PRICE**$40.45**\-15% 20dCAP**$1.9B**(48M sh)CASH**$415M**\~51 mo**Rapport Therapeutics expects topline results from its Phase 2 proof-of-concept trial evaluating RAP-219 in bipolar mania in October 2026 (company's words; month-level precision).** The readout decides whether selective neuro-receptor modulation can expand outside core focal onset epilepsy programs.**Company.** Rapport Therapeutics develops precision small-molecule medicines for central nervous system disorders. It has no commercial revenue, advancing lead asset RAP-219 across focal epilepsy Phase 3 FOCUS trials, acute bipolar mania, and long-acting injectable formulations.**Science & competition.** RAP-219 is an oral negative allosteric modulator targeting AMPA glutamate receptors associated with TARPgamma8, dampening localized cortical hyperexcitability. Rivals include Lithium (Generic / Various (originally Smith, Kline & French), Approved (1970)) and Divalproex sodium / Valproate (AbbVie, Approved (1995 for acute mania)). First-line treatment consists of oral mood stabilizers and second-generation atypical antipsychotics.Sources: [bbrfoundation.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGTXiGRlrDfxDy76-2aD53%5FYf3ZbPxMh14AgGfRfUwkuXXKp62TSm-RKRArCL7RbrDMsOExRtwqX1Xt2lxAWQPf5fgyrt540O6mkNrhBmcTFW0lJtHsPH7C295k3wcCYODYNSj5wRHQom%5FVxqMMyq-yMLDnQ2MrqXf-8pDkqWeBOYu7uE4UdA5eFLQmu7gIMj%5FKHm%5FNtvW1P%5F0rgC2M3-KkpRxMTfztM7pcIm4VNVF7lw==?ref=biostockinfo.com) · [innovationscns.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFMAMyc9NmZxR37Iv2hP7k5Sq7KGpExexm15C7UcPq5-ob-BtLF5EwnJB0XruRfglPDY05SAZpDd5CyAMFYZSwjg621VxOkv280uKp8sHliIoEL3yG947uPHEB03kFTibkRYSwMMuOta2KLXxDhxavNJGLzomIbtQBxtvjiBgjQjUY=?ref=biostockinfo.com) · [neiglobal.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHT8WpT2-JK4aS4bCq%5Fi6heOanSovXChoq5XiHO0Aw44aOfaLYgnUyHb2geW9UseEUyUEXLKbFz37bFwWyxZni8jMCEAVF98dLS2LYNTLYdAQ5g5GmdJC5IeGzyA6pv7F6N9kUJiH2DdjSfioVg4hZ7kqgHqe9Cvg==?ref=biostockinfo.com) · [drugtopics.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHuwEDpM2frhiR0h0uuKjkbLcaL4NAgo9kD2R-rQIUbmA7TM6uW7n-yPyk90l6-ac2YCQY7kWLaWim7iKqZJaM%5FNwVHJZNgqOEhEkTyqjzM9-SefuzSvpqwqL1Y3Hpiv1kjX4z-YXZkZ0Se-Inm4%5FJI9L8b9nQ1yH1a3CKRFfmeluFqM-%5FgyN17rUCjjSSR6iUcVCwrMq0KTv1-MyxeIz5k-7YHmTQOTYYJKqug?ref=biostockinfo.com) · [wikipedia.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7Z6-Ck4tVgPiCvt9dV%5F4VbGHN5bun7LnNHbcro6wgffhuUNjH-C-KGDxmXHN0KGzxZmq5%5FUOct5rvtmKDMe5pQ6HjPth3j7M-Q7SYNTOoAkPbEMEermKm3vlSujn6DITSIIWw1aHSbKIe%5FvzsaDFmyXxiUdRfPFRSK2zAxKVM3obZGXpq%5Fw==?ref=biostockinfo.com) · [veeva.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE9Oz8NOQzesRa3tIXVlUiMpw8g6LrvdiyZ02ReryUkyCd1iztwRVBZxR39ymqp7MutUcLMTvDtO5Uf%5FVFLqonw52enK2wrilW1oTnbrQ3lF14farKk5XijxBsqFFoyMcj8QpwjxrWyYm3yteGhR19xjtslDAnZzOaIdCNRsbjPzUPyevG-tCqiRVC67k4swFNhN7eTKCUZPnyQ0taZAhqNzHZDenxbWFfc47c4U3exnK4PEAPxM6Km?ref=biostockinfo.com) · [veeva.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG5%5F6rPLb6qB2JSRfzGoVggrVYy4YKjMRVsK3cs%5Fd4d1grDYzAWOPjFkz45IfHtNBy-N5jxQiRsSPixvyJ4nHbK8XIZHEk2V316XYvYN8OR-%5FnVskx%5FIs2BA8gUN3bWr8imHVTa2WSYnKonVKW-RcPrVkT5q-d7fSQOJIxZQ1Fuwzdl90GSnk8%5FIdjR5Kw4tg0Yu5F5G-hXowThlhV1fxGHPonlefA5Cr%5Flv4dzgDphC5PUDY3gyhHUMkPNqQ==?ref=biostockinfo.com) · [veeva.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHMJl8x5tNqFkiaP3YyIMYXkjuDKifak6Xqud7WKxuHrcYKKPWcNRyxGyUCuib4p1pzyHZRN-rUb50ouxN-BGduHlhqsrJbOW6zT-Ed1GS0Ek91CdT4dLI7x9YtDdSi5NtB2TcsolOTDigjLtTa8AOJwss5yQHWTOftIlMrFXcWoF1au4C0TCKsHY9aSA7Gr%5FqKF6j0FXaNytzXwIS%5Fln4D59WjMMPvxjZMUaDGynd39Oo6WX0%5FDokWPnRl?ref=biostockinfo.com)**Why it could work.** Sparing non-target brain regions avoids the sedation and metabolic weight gain of antipsychotics, following an 80% median reduction in long seizure episodes in Phase 2a epilepsy.**Why it could fail.** Complex psychiatric manic circuits may not translate from focal seizure suppression, and undefined Phase 2 trial controls risk high placebo response.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=RAPP&ref=biostockinfo.com)EIKN — Eikon TherapeuticsCATALYST**Oct 23, 2026**ConferenceRANK**80**PRICE**$8.95**\-17% 20dCAP**$485M**(54M sh)CASH**$473M**\~22 mo**Eikon Therapeutics will present Phase 1/2 clinical data for EIK1003 in advanced solid tumors on Oct 23, 2026, at the ESMO Congress in Madrid.** The presentation decides whether next-generation PARP1 selectivity enables tolerable combination regimens alongside standard chemotherapies.**Company.** Eikon Therapeutics is a clinical-stage oncology company discovering targeted small molecules. It generates no product revenue, financing multi-candidate Phase 1/2 clinical programs including EIK1001, EIK1003, and EIK1004 from cash reserves raised in its 2026 IPO.**Science & competition.** EIK1003 selectively inhibits and traps PARP1 to disrupt DNA damage repair while sparing PARP2, aiming to minimize dose-limiting bone marrow suppression. Rivals include Olaparib (AstraZeneca / Merck, FDA-approved) and Saruparib (AstraZeneca, Phase 3). The standard of care is platinum-based chemotherapy and first-generation dual PARP1/2 inhibitors.Sources: [asco.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG3Nj7F%5FYLVduIIdkGLWTzP3PAGVyNFJSE6LLkGqB2QJZxgxrMIEEm06CZjA6NIXqIhnA5ZGJwsifKrrzL1YMRbS-8V%5FlvdVVNwFl1vaNui8s-Z4wa67CI2B7dJ8ERKg0s48xeEL3WkwFeUani%5FsQ==?ref=biostockinfo.com) · [eikontx.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE6JlqcQ0y9-V7bQGXK0JUhWQsV4URUnoAl8EpU9uiPCw7WF4qDHaG5ycmBEZ5zcO3aBLIzL4vC-BnmYjQ7OSV3Gb3Z4ovZ85I0s0jJQDWpWPHsu41uwBLozFVxoXDDPaaTsdOs%5FMT%5Fwyu6bCU%5Fq11UzUyLGqQqwzKUp80k7%5FNxd0PW27Z26HtDUAXGxgVHz%5FsXJKObeFjXINuxD49e2sQq?ref=biostockinfo.com) · [onclive.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHiBMrAIkCZCaS-h2IxwP9ZuEkMIAxLO4WGKmSiwVopxZI7FPfrakQyaAlrheFAgz4qYOapSXFf5HzD5%5Fdk0S%5FYPZ2xw%5FwKrz5hze5cE%5FTHl8GkM17KPaRFcmfNXmO346aTODc6mi0Nc021lZgxQfBHrd3%5Fl6BclsQgl%5FdBD6gNq-r2Xl8NNMJUVRnwZZn1nhXtBd%5FITWU=?ref=biostockinfo.com) · [fiercebiotech.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFehLH8QIJpzNck4OPWZYb4ltIahhhP-tIM8nI3gYicW9d1wj57pt24AWb%5FVfWjejfpzwVcgP%5F1H3ewr3ebJiD6mxyVB8UJMwNBsdB3KfTNmw%5FgD9TvcNqpQQOUBvIZKVdv6tIGsDEHXWz0NfFUYbU9cmSsNCwmU6KQbxpKWAgKmgEiMubaqEBX3r1e62eevLzy%5FcMu-PgzplTca4LyuzWcsnDt82aeVEU-ug==?ref=biostockinfo.com) · [investing.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEBGHyXJ6gMFHvd1lkzL9raqG2jslxyiG9bE06yLY%5Fcvt-V46t1Tw26F%5FH9MlcF8JpIRIq6doJsFPyu-YAOOLiXlKNg4%5F-nKm-9pvChefUxpAFPIdNwO67MtghjDZZxlV8KjkyLe5YtNHt8SF2qBmWV%5FSdfBnH7XfR8eXkA%5FzUl3u9K7HsdCYjT2opleQ6rlYd-TR5K%5FjvCTYPSGOUvqUzttCJEGVTIbJ38RRNxMYAxjfLbLoFP8xkIcA==?ref=biostockinfo.com) · [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGeQi3Qaf5Zw2J5qnAEqX%5FR-sMnx7TCEUJYqvrnS9yBvmqA%5F2lCUo6VEZCG-0%5Fh7KXQrgEi1BgWTuQ2b%5Ffc3HWzsGZVddMCsql7OQtfRLPPYPFWNtxJ3k8JUyUrZ8PH3xgXAOP8vZ-dQEkwqQXrF9bKNc9n2aefdddGhB3ie-eAWqXzVK2PRs-SiEuNVCtysxDGBF%5F?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFAWMTNfNax-rHfmzH-gb71L2eyQyZTM4YcK2V3We2OPv6ebaPiVN9pwir7BU5MpQY3MY-QfchZ4fvs4LQuOCOoBSTk%5F5oY4OWnWWLMEtJYAo2mPBsAdvtfFhv2Fk2pw4ZawJ3jdx2pFV4fDQPl?ref=biostockinfo.com) · [delveinsight.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHnRgeQ3KJyPyOuAa8Zhix-dW7EgCCGpRTRTHGm0ahjm4SaEJ0Bc95kWCipwUeUefakJuVJ7DWKPsUy6D2hRGaDeIihjGP809rb-2lNrjYIwMZoMYyqGxMZSDuIHcYzstW6jwdyu%5FKHZnb%5FQeuORp-ljy4KkCHdk2HV9KLNEIRY8dYAJXSt?ref=biostockinfo.com)**Why it could work.** Spared PARP2 activity could allow full therapeutic doses alongside paclitaxel or abiraterone without severe overlapping bone marrow suppression.**Why it could fail.** Combining targeted agents with cytotoxic chemotherapy frequently triggers dose-limiting neutropenia or neuropathy, forcing dose reductions that dilute tumor responses.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=EIKN&ref=biostockinfo.com)PALI — Palisade BioCATALYST**Oct 9–Oct 14, 2026**ConferenceRANK**80**PRICE**$1.59**\-23% 20dCAP**$277M**(174M sh)CASH**$121M**\~80 mo**Palisade Bio will present clinical data for PALI-2108 at the ACG Annual Scientific Meeting between Oct 9–Oct 14, 2026.** The presentation decides whether gut-restricted prodrug cleavage maintains mucosal healing without typical PDE4 emetic toxicity.**Company.** Palisade Bio is a clinical-stage biopharmaceutical company developing localized oral prodrugs for inflammatory bowel disease. It generates no commercial revenue, deploying its cash balance toward Phase 2 ASCENTRA trials in ulcerative colitis and Crohn's disease.**Science & competition.** PALI-2108 is an oral prodrug that cleaves locally in the ileum and colon into an active PDE4 inhibitor, reducing mucosal inflammation while minimizing systemic exposure. Rivals include Tofacitinib (Xeljanz) (Pfizer, Approved: 2018) and Upadacitinib (Rinvoq) (AbbVie, Approved: 2022). The standard of care is oral 5-aminosalicylates with corticosteroids, followed by biologics or targeted oral small molecules.Sources: [palisadebio.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjqw5hf009tE83EYxNDsyLNqA4Vssjwv6IA2fXyL7Yrdx-cGWdIW-4c25kAzq9t1ynnu4HvFfXRCIqYRLbdOZu06DGKQrNWn11uxBWBIR9IIqNafVYEYHacAi6BmfpEGKDezOg3g==?ref=biostockinfo.com) · [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF07AzbN3wqOgSMmNqahuDQtmAgbx%5F4H4wLyD9l9fQ-L2J486FHgxoPPaCthM%5FpGX87eZcAuVjL91bTxwuIdjRpqLZ0t3NQRCAkEecQT-MPaTv-6UVXEVYpDiLafSgEnj8aC9KLKBig?ref=biostockinfo.com) · [allclinicaltrials.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGjvPpLxrdpXN-hEfU5dRwhPOd6XeRhtEtK4S-O6uN1RNPrb%5FYXT5l7evjX711AMlAzJOPFwBdD7nHiUrLxQQDrXE59A1CGgM7AeBmZn0w6trursFwhv9m-Iaxda%5FVvIFHi%5FI6ivfNzGNuNlU0bN2S%5FfF7Td2fp0wpxEeyn-IGATS7du4RpfA==?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF79B%5FMc5zObMvj5-X-m0tFyJIfvbJbp6K19-F59jxM5L1oScU4oHqpuaJ%5FH0M79AQmGhBBYmMTCJU8xtktIrZHjmH2CSD9id3fnWPtgp5%5F98kpEaHvUossA49wlBnWJ3FnZd4Az2yLO4vWsbvN?ref=biostockinfo.com) · [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFH3hrQKVBgpyFuHIXXG8tIBFMiiYaKCr7xvtEoRPj-y7gbfptoCUU0XCN%5FVRyxFiG6bSjHTPB4xtCkEsNyFemFTgGf4Ee4pIvRaigR8Lmjf1i5xzrsewyraWvROCtO42jCE8UPYNZX1kxKVsdtEhKr1v7x8F8cZki3?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEGOLEY4kAxJ4hjD9-9RRwwij7YixhY4jrQYFpGxnSif0LAGS8EfiQmmopLKEE8XHgdKSLaYDmxs1U6vvSW%5FwbDVCI8Q-CnC2Jrx95hvbjuDkb7-qz52szPdLT04jIhCQSHlzc7m5lJ1CG8c1J%5F?ref=biostockinfo.com) · [appliedclinicaltrialsonline.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFRAi0AKY-ge2xJt9n5bFI9x-oqs%5FUs-VilCtQ6iMCDxwDmjxHnThTQsody9vrpBlliGhwLitShBVewHEwcKlF7ptVbZSO49aVAQlKx3xS%5FEORowDlduMmj6aXPRWtbx3vfJb2ET0eSVohQPn6IK6JaojuyJL8Fi25F%5F1L8Y0tNR%5FJoQ39%5F7V2B2uXqMBiYjlwjKjz-NX0zRAYozJg2bXbEEZM=?ref=biostockinfo.com) · [delveinsight.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHfgA0OUwxBSKOc4ch1ZCfGR4FnPZRa3EBiWhibTiqsnZWnwB6PXcp2ME-HxvPNbj3-UgL%5FfM1K58MHosIfacGHZShz834s1mXohO-fzW7j0Cyc4t3BTqYANMn6bO8vSt-vVJeQJhPPqO-50JJF%5FBz%5FxgV7hJXtyN3eHW54aK2msVkXAJ7oHSvgOkR2?ref=biostockinfo.com)**Why it could work.** Localized gut release avoids systemic PDE4-mediated emesis, building on preliminary data where 5 of 5 ulcerative colitis patients achieved clinical response.**Why it could fail.** Prior clinical data rests on only ten total patients without placebo controls, risking significant regression to the mean in larger trials.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=PALI&ref=biostockinfo.com)IMCR — Immunocore HoldingsCATALYST**as early as the end of 2026**Data readoutRANK**80**PRICE**$32.00**\-12% 20dCAP**$1.6B**(52M sh)CASH**$477M**\~164 mo**Immunocore expects topline overall survival data from the Phase 3 TEBE-AM trial of KIMMTRAK (tebentafusp) in advanced cutaneous melanoma as early as the end of 2026 (company's words; quarter-level precision).** The event decides whether the ImmTAC platform can replicate uveal survival benefits in post-checkpoint skin melanoma.**Company.** Immunocore develops T cell receptor bispecific immunotherapies. Commercial revenue from KIMMTRAK in metastatic uveal melanoma funds an extensive oncology and autoimmune pipeline, including brenetafusp and early-stage programs in atopic dermatitis and HIV.**Science & competition.** Tebentafusp is a bispecific protein redirecting CD3-positive T cells to gp100 presented by HLA-A\*02:01 on melanoma cells. Rivals include Opdualag (Bristol Myers Squibb, FDA-approved (2022)) and Amtagvi (Iovance Biotherapeutics, FDA-approved (2024)). The standard of care is dual checkpoint inhibition, anti-PD-1 monotherapy, or targeted BRAF/MEK combinations.Sources: [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEgjVUVdiC%5FjotUUTUU99-styBcnxWxrQ3ipZ99A4agYQ%5FEyUdDc7fmkMvJnonF3DR4Q3wba9fXo56YPQ7b2ecK4rUbcbFz-57k7pq%5F5Y9PWDsrafKKRaDahe4Krsoieq%5F6Rt4=?ref=biostockinfo.com) · [immunocore.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGEwF3XNXzcY5RGSLHuKuHeE1Cz4wp42s9Rtub9VUwy3OXnHiPYPGnZ6bG6LNBAnEwOHB6fmlrIJ5OpN5Ly30WGri6nky3E27ZxZueZnYr4ZcIn6otYEcHp1Rbq0AE0tu-Jd3SlKu91upXZ-XaPn-Sa7t%5FToZCrePpB69aN8kfQjj-3z0cKKfq9Ozp7txxnWN-2RwA6AcdLWxSVXj1jOLVqCz1QkfmkJs0WkoHOVsKuFdwC%5FxeUM8C6dBQU0GcxlrlnBeFXMS5jdXxqdf8rt7Zhtfk3oxWW%5FYzAhNOwIirrc5gw5hHYYWRh57gOtylAZhoOJzaSefrgXP8h%5FHrSZwqcCNN3LHQNJilOZM09coiVnrDF-7DJmKomyLwdlfhweogRtUphKqZ-N6qyRqtiOIntZ%5FxC9mxldu4URtyVsMXM82RV8w==?ref=biostockinfo.com) · [merlintrader.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHt-ZCQ9A8PHj0id30%5F7TC4I3Y36H0QBDvMaLY2f7sMdaEb29n2yzHFIrl%5FD-KGQ2j0GRgRLO2qlEX8Pp2bQEJhvGVH2iCjRpArYkaSTy6l1d6-NKuDKpuBbwSxipvMD2G5sRUrugoRSmBLvW09MIeTrGbY0igESGwJ3NsEmw==?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHomCXzNG9KpoMw5sxumF7b8TI5iWkkwAkIMuMj-FZcJALN6JTjDUBlJe9y7Al51c1zKun0EL1RS3aY8e3-OZdv1rP-GUC11XvhLsvyfwNW-PU6hl79b3Y-JLrY-Gqf58P6B6FyfLRZVOCz3qk=?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFxSzQ1pTTx9FHq5M3L2ThTSQIfB%5FTDO8Q3zpv0eSmOawlJpL18FKgxwDkfxCmMhevzqJCLHjwMO8Gs1Gn%5Fdx6xqJZnW27tP3Hf7n2cn5Dhoj-dHZk9lAFrfIrb3E2B7bX8ELEJ9AGB2HPwoKI=?ref=biostockinfo.com) · [pharmaceutical-technology.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNXJRrt10Z7t%5F5QPgj8zm%5F%5FsOKLYzMzkGJrl8da1dwGbI62YxeSKmpG9EiuEuTSEghQZz4J4bzfZVH2gT7aQ37ZPTHxB3iqxgXn4ALl6HcchTJbUhRKNoLcSo%5FqUp2RFC4ai%5FrB-bXBYqQtBmQ6279gSDogc-lPFRuXstFY8drixus8nAJKYEYrkbigBf1It2-jTjg7FpiTZv4kPDhtemw3I76PfFD4QaH?ref=biostockinfo.com)**Why it could work.** Tebentafusp doubled five-year overall survival rates to 16% in metastatic uveal melanoma, confirming that redirected T-cell activity can extend survival without high tumor response.**Why it could fail.** Cutaneous melanoma post-PD-1 progression exhibits deep immune exhaustion that could neutralize redirected T cells, while restricting eligibility to HLA-A\*02:01-positive patients.**Recent development.** On September 14, 2026, Immunocore announced that it completed target patient enrollment of 540 patients in the global Phase 3 TEBE-AM trial ([immunocore.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFXa8A5BAB9rLIv4-KCFTViomrzM8oumR0TXCPKtY4vsCF4B-F%5FLEBajv0CqiAxUPr2La9K2cipKtoXvRYvAkbZt-mlVVDnW4m9EPyeCb8iyIc5P9g8vuzpJhQLnRMYT6NqGf2bVuuGOtlVkDUCVpv0KuOIGIuJp73iKxSvEuVHVhh820p0nrdzfoTtOP9XnWXRFAnY%5FGkxXmm9pzsfefzWOXRo1TdWoEBds84%5FUsunT8llnexlpPTprQ885MFBhmMqul%5FYeh739MH2aLm3Cm%5FGOvNxbVJZm5UJ%5FXjK4JsnItcH93AOuwcA7e%5FZMKul9I2xMnVI1p5YUHRP%5FtYJs2J06Zd8N3tGbMR%5FHFzOiw99pt%5FDg9w-3sY=?ref=biostockinfo.com)).[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=IMCR&ref=biostockinfo.com)NAMS — NewAmsterdam PharmaCATALYST**by year end 2026**Data readoutRANK**80**PRICE**$22.49**\-19% 20dCAP**$2.7B**(120M sh)CASH**$646M**\~54 mo**NewAmsterdam Pharma expects topline data from the Phase 3 RUBENS trial evaluating obicetrapib in type 2 diabetes or metabolic syndrome by year-end 2026 (company's words; quarter-level precision).** The readout determines whether CETP inhibition maintains potent lipid lowering without impairing glycemic control.**Company.** NewAmsterdam Pharma is a clinical biopharmaceutical company developing oral non-statin therapies for cardiovascular risk. It has no commercial product sales, partnering obicetrapib with Menarini Group in Europe while preparing for initial commercial launches in late 2026.**Science & competition.** Obicetrapib is an oral cholesteryl ester transfer protein inhibitor designed to block transfer of cholesterol to atherogenic particles, substantially lowering LDL-C. Rivals include Ezetimibe (Merck / Organon, FDA-approved) and Evolocumab (Amgen, FDA-approved). The standard of care is maximally tolerated statin therapy combined with ezetimibe or injectable PCSK9 inhibitors.Sources: [firstwordpharma.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHAqYFcU7d4FvDCRE0Q%5FEWsZsKwNU1wzBupRbhC0Bv-sKw7AmAlb0aY4pi4EiICC3X8g958PwwaNutwNY8IHqpYDeuq4xC0EDgbfe8Lu9UzA8sTteyQUCfbmKGP1kGJSN0YRDQX?ref=biostockinfo.com) · [mdlinx.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGiHjURrKUoohdw5RyuQgPMbmLlKxARh1pB1ZvHanf47H4Pqjl02hKB3IlEKYB62-aVWAQPT0BAJQtHhtrRifQXCBDHDwu0-lkq3CdYNuLCqZebvHri8UScpbcxwdp7Sfj8rh1gHl87v38m2eJL5Ej6lb7ZsLIbuIjWTJxA3oSyGWxWLEH1T9USD1wVJtfAXlj6pTzIANR3GSXZmcQCoIjXJj2vAYbx83hE6%5FzeD48%5FWaz7GFoJpWSz804=?ref=biostockinfo.com) · [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHA0E2lXPv6I%5FhcoOeYGC9GIzmtMXkH3UUa9eSZFPB24tBEBihxNEi3DnQ%5FOGv4mTviJa4LgAxwoOswHCQgPSO%5FwIR-oNKGFO-jrH5o4g-ZNXlOcXDQDcUPuWqWOfypNCa32Brt3ht02387DfHK-ExCAWQt6G8oNo1BQfrhag==?ref=biostockinfo.com) · [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHcgqlcvfUXhNgV8RloxQVBow651GW0sWoDfMosS-NgCbtu%5F4RUqDgNRPu-RxEs3DYPBPlcno4RUHMZjHSi2XJX0LtgpEpdkiAZYRZRcnv-MAoq%5Fs0s9h3q7lw4GnbutuXJeuds-2w=?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGLMFdXR%5FCoyrMbUZIOYVD7dVBQzlRXNulB9tSa0lYsUT1A6vxkz68-HepEmnpHh7u6a0QdXGbssz8ue6jymzyglO2MJ7-f6N5CmX5ewW8FEMxmVhSLGEDM4MZ4OniPi-DcrQz4raRaKcOqXYg=?ref=biostockinfo.com) · [firstwordpharma.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGuKBTZZF6AmLDDe8sGbJcC9eupeQtTfr3-Kw7LQ797X3JWQl4EvyF0epkxliKFDVNEYq1VPK3-NlB1U1ngowYPoWOS-ZTOy4VrNvrg%5FRpQ8GJ4X9EOrNaPpNVx8rP9BfQG%5FmA=?ref=biostockinfo.com) · [newamsterdampharma.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGmcTGWa2qkeXFTq75G60pJkeXG9D67XlqLifR91wPGRnafpj9%5FwOh735O64NSeg9gPEbFIQmx71AMVAQShohk8MnKrF2dnVVskCFknM0C2BouYbeuSp-fZRbzpyG0io4TJY5nOht1RwdNcwzxQDhO-fzX2?ref=biostockinfo.com) · [seekingalpha.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQErJLPMFVG6%5F5rIL-cYCkwD8Ayva2KrDEHToZ7EAaWF2%5FYFGzF2GR6TUFeE1nUfKdgsw2HePE%5FY2ktT10huUPrdkQsfZAH77wcX8mMJYL-VY%5FyI8LIBIWzh1aKhcrGIB2z0JiO-fVFRrK0WkLFA3dC9YgEizwVTcIDEafjhebe02qCGYvGDot3HpB73rYGceDP9nhH5kxrvoXYd8tBzW2DxKi7fkptmeutWBw==?ref=biostockinfo.com)**Why it could work.** Obicetrapib demonstrated 40% to 50% LDL-C reductions across prior Phase 3 trials and recently received a positive CHMP marketing opinion in Europe.**Why it could fail.** Historical CETP inhibitors failed in late-stage cardiovascular trials, and any emergence of adverse glycemic regulation in diabetic patients would restrict use.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=NAMS&ref=biostockinfo.com)WatchlistADCT — ADC TherapeuticsCATALYST**end of 2026**Data readoutRANK**79**PRICE**$1.05**+9% 20dCAP**$134M**(128M sh)Cash $196M, \~23 moFiling warningADC Therapeutics expects full data from the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with glofitamab in 2L+ DLBCL by the end of 2026 (company's words; quarter-level precision). This combination readout follows pre-sBLA FDA feedback citing substantial benefit-risk concerns due to an imbalance in Grade 5 fatal events in the LOTIS-5 trial. The company initiated a 17% workforce reduction in June 2026 to conserve its cash runway into 2028.**Filing flag.** During the August 2026 pre-sBLA meeting, the FDA noted substantial concerns regarding the benefit-risk or verification of clinical benefit observed in the LOTIS-5 trial based on an imbalance in Grade 5 events.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=ADCT&ref=biostockinfo.com)CLDX — Celldex TherapeuticsCATALYST**September/October 2026**Data readoutRANK**79**PRICE**$38.24**\-4% 20dCAP**$3.0B**(78M sh)Cash $665M, \~34 moCelldex expects Phase 3 topline data from the EMBARQ-CSU 1 and EMBARQ-CSU 2 trials of barzolvolimab in chronic spontaneous urticaria in September/October 2026 (company's words; month-level precision). Prior long-term Phase 2 data showed sustained efficacy, with up to 64% of angioedema patients remaining symptom-free at Week 76\. The readout serves as the primary registrational test following the termination of Celldex's mid-stage prurigo nodularis program in July 2026.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=CLDX&ref=biostockinfo.com)IRD — Opus GeneticsCATALYST**Oct 17, 2026**RegulatoryRANK**79**PRICE**$5.18**+26% 20dCAP**$431M**(83M sh)Cash $80M, \~24 moFTDSPAThe FDA has set a PDUFA action date of Oct 17, 2026, for the supplemental New Drug Application of phentolamine ophthalmic solution 0.75% in presbyopia. Partnered with Viatris, the application is supported by Phase 3 VEGA-3 data demonstrating statistically significant 15-letter near visual acuity gains. Opus Genetics maintains a funded cash runway into 2029 across its rare inherited retinal disease gene therapy pipeline.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=IRD&ref=biostockinfo.com)OCS — Oculis HoldingCATALYST**around year-end**Data readoutRANK**78**PRICE**$10.14**\-23% 20dCAP**$689M**(68M sh)Cash $46M, \~8 moOculis Holding expects topline data from the registrational PREDICT-1 trial of licaminlimab in dry eye disease around year-end (company's words; quarter-level precision). The trial evaluates an anti-TNF biologic eye drop using a genotype-selected precision medicine approach. Although cash and investments provide runway, the company's standalone liquid cash balance stands at eight months of runway ahead of planned Q4 regulatory filings.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=OCS&ref=biostockinfo.com)ACRS — Aclaris TherapeuticsCATALYST**Fourth Quarter 2026**Data readoutRANK**78**PRICE**$5.50**\-13% 20dCAP**$810M**(147M sh)Cash $197M, \~38 moAclaris Therapeutics expects topline data from a randomized, double-blind Phase 2 trial of its anti-TSLP antibody bosakitug in 109 patients with atopic dermatitis in the Fourth Quarter 2026 (company's words; quarter-level precision). The readout assesses percent change in EASI at week 24 to establish proof-of-concept against established Th2 biologics. Aclaris bolstered its cash position following the second quarter with $40.2 million in ATM gross proceeds.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=ACRS&ref=biostockinfo.com)BNTC — Benitec BiopharmaCATALYST**Oct 27–Oct 30, 2026**ConferenceRANK**78**PRICE**$11.02**\-15% 20dCAP**$379M**(34M sh)Cash $176M, \~106 moODDFTDBenitec Biopharma will present additional interim clinical study results from its Phase 1b/2a trial of BB-301 in OPMD-related dysphagia at the ESGCT Annual Congress between Oct 27–Oct 30, 2026\. Prior data showed durable functional responses at 12 and 24 months in Cohort 1 and deep early responses in Cohort 2\. FDA minutes regarding pivotal study design are expected in October 2026 ahead of mid-2027 pivotal trial initiation.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=BNTC&ref=biostockinfo.com)DTIL — Precision BioSciencesCATALYST**by year-end 2026**Data readoutRANK**78**PRICE**$6.67**\-24% 20dCAP**$184M**(28M sh)Cash $101M, \~23 moRPDODDFTDPrecision BioSciences expects initial safety data from the Phase 1/2 FUNCTION-DMD trial evaluating PBGENE-DMD in Duchenne muscular dystrophy by year-end 2026 (company's words; quarter-level precision). The ARCUS in vivo gene editing therapy targets exon 45-55 deletions to produce near full-length dystrophin protein. Dosing commenced in August 2026 under specialized immune modulation, supported by cash reserves funding operations through 2028.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=DTIL&ref=biostockinfo.com)VIR — Vir BiotechnologyCATALYST**in the fourth quarter of 2026**Data readoutRANK**78**PRICE**$10.60**+15% 20dCAP**$1.8B**(169M sh)Cash $965M, \~57 moVir Biotechnology expects topline data from the Phase 3 ECLIPSE 1 trial evaluating elebsiran and tobevibart in chronic hepatitis delta in the fourth quarter of 2026 (company's words; quarter-level precision). Mid-stage SOLSTICE data reported an 88% undetectable HDV RNA rate at Week 96 for the combination. The trial represents the first registrational test for the regimen, supported by $1.01 billion in cash and collaboration capital.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=VIR&ref=biostockinfo.com)INO — Inovio PharmaceuticalsCATALYST**Oct 30, 2026**RegulatoryRANK**77**PRICE**$1.24**+2% 20dCAP**$128M**(103M sh)Cash unavailablefinancing filed since the cash dateAccelerated ApprovalPriority ReviewBTDODDFiling warningThe FDA has set a target PDUFA date of Oct 30, 2026, for the Biologics License Application of INO-3107 in recurrent respiratory papillomatosis. However, the FDA noted a preliminary review concern that Inovio has not submitted adequate information to support accelerated approval eligibility. The company held $36.7 million in cash at mid-year, funding operations into late first quarter 2027.**Filing flag.** In the file acceptance letter, the FDA noted as a potential review issue its preliminary conclusion that the company has not submitted adequate information to support accelerated approval eligibility.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=INO&ref=biostockinfo.com)TRDA — Entrada TherapeuticsCATALYST**by the end of 2026**Data readoutRANK**77**PRICE**$6.75**\-11% 20dCAP**$263M**(39M sh)Cash $193M, \~17 moRPDEntrada Therapeutics expects open-label clinical data from Cohort 1 of its Phase 1/2 ELEVATE-44-201 trial of ENTR-601-44 in Duchenne muscular dystrophy amenable to exon 44 skipping by the end of 2026 (company's words; quarter-level precision). Initial blinded data met primary safety endpoints and demonstrated preliminary motor function improvements. The company held $223.0 million in cash at June 30, 2026, providing runway into the third quarter of 2027.[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=TRDA&ref=biostockinfo.com)The TakeLate-2026 catalyst setups split into high-stakes regulatory expansions and binary mechanism-validation readouts against a restrictive macro tape. With the 10-year Treasury yield pinned at 5.00% and market breadth weak at 30%, capital remains unforgiving of ambiguity. Regulatory catalysts for commercial-stage platforms like Ionis (IONS) and Agios (AGIO) offer clear cash-flow asymmetry because their commercial distribution is established and downside risk is partially absorbed near range lows. Conversely, Inovio (INO) faces acute binary danger given explicit FDA skepticism regarding accelerated approval eligibility and limited cash. Across mid-stage trials, Rapport (RAPP) and Celldex (CLDX) provide defined upside if novel neuro-psychiatric or immunology biology translates into registrational cohorts, whereas Palisade (PALI) and ADC Therapeutics (ADCT) must overcome micro-cohort limitations and prior regulatory safety warnings. In this environment, names with multi-year runways and non-dilutive partner backing provide the safest risk-adjusted exposure.*How the scanner ranks names, estimates cash and reads dates is explained in [the methodology note](https://www.biostockinfo.com/methodology/). Companies' own words and SEC filings are the only source for every date above; rivals are named from a cited web search. Not investment advice.*DisclaimerFor information and education only; not investment advice or a recommendation to buy or sell any security. This AI-assisted newsletter may contain errors or omissions, and catalyst dates can change. Verify details against original sources and do your own research. Biotechnology investing involves substantial risk, including loss of capital. |
| --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |